Systemic Immune-Inflammation Index (SII) and Expanded Disability Status Scale (EDSS) changes in multiple sclerosis patients after cyclophosphamide therapy | Synapse
March 3, 2026
Systemic Immune-Inflammation Index (SII) and Expanded Disability Status Scale (EDSS) changes in multiple sclerosis patients after cyclophosphamide therapy
Key Points
Cyclophosphamide therapy correlates with significant changes in the expanded disability status scale in multiple sclerosis patients.
Increased systemic immune-inflammation index after treatment emphasizes its role in tracking MS progression and response.
Observational analysis of multiple sclerosis patients receiving cyclophosphamide therapy shows a clear trend towards improved EDSS scores over time.
Further validation is needed to establish broader implications of SII and EDSS changes in managing multiple sclerosis.